Shire stock up 1.3% after premature infant treatment meets secondary endpoints in midstage trial

Shire Plc shares rose 1.3% early Thursday after its premature infant treatment missed its primary endpoint but met two secondary endpoints in a phase 2 trial. The treatment, an investigational protein replacement, didn't reduce the severity of a rare eye condition, but did have clinically relevant effects for two lifelong conditions: development of a chronic lung disease and a type of brain injury, the company said. Nearly 10% of U.S. babies were born premature in 2014, according to the Centers for Disease Control and Prevention. Shire shares rose 8.0% over the last three months, compared with a 0.3% rise in the S&P 500 .

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.